Frost & Sullivan identifies 10 lucrative growth opportunities in Women’s Healthcare by 2030
With the requirement to deliver health equity for 4.3 billion women globally, the analysis highlights Women in Transition Symptoms Management & Holistic Care as an untapped high-growth potential market. The changing landscape of women healthcare needs presents 10 lucrative growth opportunities by 2030 including:
A need for screening beyond breast cancer in emerging markets
Women-specific care for cardiac and diabetes
A need for affordable menstrual care solutions in emerging markets.
Advanced fertility solutions for developing markets
Increasing life expectancy and demand for longevity solutions presents opportunities for healthcare, wellness, cosmetics, aesthetics industries
Sexual health solutions will be required for menopausal women/cancer patients.
"To improve women's healthcare, we need the healthcare sectors to move beyond male mice representation in pre-clinical trials and increase female representation from 20 percent to more," said Frost & Sullivan’s Healthcare and Life Sciences Partner and Senior Vice President, Reenita Das. "Additionally, despite the readiness of technology to deliver better healthcare for women, the existing policy and reimbursement systems are refraining them from taking advantage, so it is time for governments and concerned agencies to mull over such policies and change them."
She added: "The step toward health equity begins with correcting language or terminology we use. It is better to call 'women in transition' than menopause because it lasts for 20/30 years; hence, it is not a 'pause'."
Reimagining Women's Health is the latest addition to Frost & Sullivan's Healthcare analysis available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.